KR970701004A - 키메라 cd4 수용체-포함 세포에 의한 hiv 감염 세포의 표적화 세포용해 - Google Patents

키메라 cd4 수용체-포함 세포에 의한 hiv 감염 세포의 표적화 세포용해

Info

Publication number
KR970701004A
KR970701004A KR1019960704450A KR19960704450A KR970701004A KR 970701004 A KR970701004 A KR 970701004A KR 1019960704450 A KR1019960704450 A KR 1019960704450A KR 19960704450 A KR19960704450 A KR 19960704450A KR 970701004 A KR970701004 A KR 970701004A
Authority
KR
South Korea
Prior art keywords
cell
cells
receptor
fragment
hiv
Prior art date
Application number
KR1019960704450A
Other languages
English (en)
Other versions
KR100289253B1 (ko
Inventor
시드 브라이언
바나푸어 바백
로미오 찰스
콜라누스 발데마
Original Assignee
데이비드 제이. 글래스
더 제너럴 허스피탈 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 제이. 글래스, 더 제너럴 허스피탈 코퍼레이션 filed Critical 데이비드 제이. 글래스
Publication of KR970701004A publication Critical patent/KR970701004A/ko
Application granted granted Critical
Publication of KR100289253B1 publication Critical patent/KR100289253B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)

Abstract

본 발명은 (a) HIV- 감염된 세포를 특이적으로 인식해서 결합할 수 있지만 HIV 감염을 매개하지는 않는 CD4의 단편을 포함하는 세포외 부분 및 (b) 치료세포에게 수용체-결합 HIV-감염 세포를 파괴하도록 신호할 수 있는 세포내 부분을 포함하는, 막-결합 단백성 키메라 수용체를 발현하는 유효량의 치료세포를 포유동물에 투여하는 과정을 포함하는 포유동물에서 HIV- 감염된 세포에 대하여 세포 면역반응을 지시하는 방법을 제공하는 것이다. 본 발명은 또한 키메라 수용체를 발현하는 세포들 및 키메라 수용체를 코드화하는 DNA 및 벡터들에도 관계한다.

Description

키메라 CD4 수용체- 포함 세포에 의한 HIV 감염 세포의 표적화 세포용해
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. (a) HIV- 감염된 세포를 특이적으로 인식해서 결합할 수 있지만 HIV 감염을 매개하지는 않는 CD4의 단편을 포함하는 세포외 부분 및 (b) 치료세포에게 수용체-결합 HIV - 감염 세포를 파괴하도록 신호할 수 있는 세포내 부분을 포함하는, 막-결합 단백성 키메라 수용체를 발현하는 유효량의 치료 세포를 포유동물에 투여하는 과정을 포함하는 포유동물에서 HIV-감염된 세포에 대하여 세포 면역반응을 지시하는 방법.
  2. 제1항에 있어서, 상기 CD4 단편이 아미노산 1-394 또는 아미노산 1-200으로 구성되는 방법.
  3. 제1항에 있어서, 상기 CD4 단편이 제26도에 도시된 CD7 막간 도메인에 의해 또는 제25도에 도시된 사람 IgC1 분자의 힌즈,CH2 및 CH3 도메인들에 의해 상기 세포내 부분으로부터 분리되어 있는 방법.
  4. 제1항에 있어서, 상기 CD4 단편이 상기 치료 세포막으로부터 적어도 48Å 또는 적어도 72Å 정도 떨어져 있는 방법.
  5. 제1항에 있어서, 상기 세포내 부분이 T 세포 수용체 단백질, B 세포 수용체 단백질, 또는 Fc 수용체 단백질의 신호- 변환 부분인 방법.
  6. 제5에 있어서, 상기 T 세포 수용체 단백질이인 방법.
  7. 제1항에 있어서, 상기 치료 세포들이 (a) T 림프구; (b) 세포독성 T 림프구; (c) 자연세포 독성세포; (d) 호중구; (e) 과립구; (f) 대식세포; (g) 비만세포; (h) 헬라(HeLa) 세포; 및 (i) 태아 간세포(ES)로 구성되는 군으로부터 선택되는 방법.
  8. 제1항에 있어서, 상기 수용체가 CD7 막간 부분, CD5 막간 부분 또는 CD34 막간 부분을 포함하는 방법.
  9. 제1항에 있어서, 상기 CD4 단편이 상기 치료 세포막으로부터 하나 이상의 단백성 알파나선에 의해 분리 되어 있는 방법.
  10. (a) HIV-감염된 세포를 특이적으로 인식해서 결합할 수 있지만 HIV 감염을 매개하지는 않은 CD4의 단편을 포함하는 세포의 부분 및 (b) 치료세포에게 수용체- 결합 HIV - 감염 세포를 파괴하도록 신호할 수 있는 세포내 부분을 포함하는, 단백성 막- 결합 키메라 수용체를 발현하는 세포.
  11. 제10항에 있어서, 상기 CD4 단편이 아미노산 1-394 또는 아미노산 1-200으로 구성되는 세포.
  12. 제10항에 있어서, 상기 CD4 단편이 제26도에 도시된 CD7 막간 도메인에 의해 또는 제25도에 도시된 사람 IgG1 분자 힌즈, CH2 및 CH3 도메인들에 의해 상기 세포내 부분으로부터 분리되어 있는 세포.
  13. 제10항에 있어서, 상기 CD4 단편이 상기 치료 세포막으로부터 적어도 48Å 또는 적어도 72Å 정도 떨어져 있는 세포.
  14. 제10항에 있어서, 상기 세포내 부분이 T 세포 수용체 단백질, B 세포 수용체 단백질, 또는 Fc 수용체 단백질의 신호- 변환 부분인 세포
  15. 제14항에 있어서, 상기 T 세포 수용체 단백질이인 세포.
  16. 제10항에 있어서, 상기 수용체가 CD7 막간 부분, CD5 막간 부분 또는 CD34 막간 부분을 포함하는 세포.
  17. 제10항에 있어서, 상기 CD4 단편이 상기 치료 세포막으로부터 하나 이상의 단백성 알파 나선에 의해 분리되어 있는 세포.
  18. 제10항의 키메라 수용체를 코드화하는 DNA.
  19. 제18항의 키메라 수용체 DNA를 포함하는 벡터.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960704450A 1994-02-14 1995-01-12 키메라cd4수용체-포함세포에의한hiv감염세포의표적화세포용해 KR100289253B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19539594A 1994-02-14 1994-02-14
US08/195,395 1994-02-14
US08/284,391 US5851828A (en) 1991-03-07 1994-08-02 Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US08/284,391 1994-08-02
PCT/US1995/000454 WO1995021528A1 (en) 1994-02-14 1995-01-12 Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells

Publications (2)

Publication Number Publication Date
KR970701004A true KR970701004A (ko) 1997-03-17
KR100289253B1 KR100289253B1 (ko) 2001-11-30

Family

ID=26890956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960704450A KR100289253B1 (ko) 1994-02-14 1995-01-12 키메라cd4수용체-포함세포에의한hiv감염세포의표적화세포용해

Country Status (21)

Country Link
US (3) US5851828A (ko)
EP (1) EP0750457B1 (ko)
JP (1) JP3832850B2 (ko)
KR (1) KR100289253B1 (ko)
CN (1) CN1318576C (ko)
AT (1) ATE308888T1 (ko)
AU (1) AU690204B2 (ko)
BR (1) BR9506783A (ko)
CA (1) CA2182890C (ko)
CZ (1) CZ293969B6 (ko)
DE (1) DE69534589T2 (ko)
DK (1) DK0750457T3 (ko)
ES (1) ES2249766T3 (ko)
FI (1) FI120264B (ko)
HU (1) HU220100B (ko)
IL (1) IL112390A (ko)
NO (1) NO319378B1 (ko)
NZ (1) NZ279123A (ko)
PL (1) PL180066B1 (ko)
UA (1) UA42760C2 (ko)
WO (1) WO1995021528A1 (ko)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6407221B1 (en) 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
CZ291754B6 (cs) * 1993-07-16 2003-05-14 The General Hospital Corporation Proteinový chimerní receptor, terapeutická buňka, DNA kódující chimerní receptor a vektor
DK0781095T3 (da) * 1994-08-02 2003-06-23 Gen Hospital Corp Celler der bærer CD4 lokkeduereceptorer og beslægtede molekyler og fremgangsmåder
GB9520641D0 (en) * 1995-10-10 1995-12-13 Medical Res Council Improvements in or relating to protection against intracellular infection
AUPN980796A0 (en) 1996-05-13 1996-06-06 Australian Membrane And Biotechnology Research Institute Improved reservoir components
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
GB9925853D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
DE19957838C2 (de) 1999-11-25 2002-11-21 Pette Heinrich Inst Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
IN2014DN06624A (ko) 2005-10-18 2015-07-10 Univ Colorado
EP2031646A4 (en) * 2006-06-22 2012-05-30 River Bell Co TREATMENT DEVICE, TREATMENT METHOD AND PLASMA SOURCE
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
EP3725319A1 (en) * 2010-04-14 2020-10-21 Roger Williams Medical Center Methods and compositions for treating hiv
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EP2847223B1 (en) 2012-05-07 2019-03-27 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
PT2884999T (pt) 2012-08-20 2021-01-05 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
EP3261651B1 (en) * 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
KR20180010229A (ko) 2015-05-20 2018-01-30 더 브로드 인스티튜트, 인코퍼레이티드 공유 신생항원
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
EA201890782A1 (ru) * 2015-09-22 2018-09-28 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ перенацеливания t-клеток для лечения инфекции hiv
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN106267409B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物治疗反应器
CN106178163B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物细胞免疫治疗仪
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110612119A (zh) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
EP3589295A4 (en) 2017-02-28 2020-11-04 Endocyte, Inc. COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF
CA3059643A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
KR20240059648A (ko) 2017-04-19 2024-05-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
CN107014658B (zh) * 2017-05-27 2023-08-25 四川省肿瘤医院 提取游离细胞的方法及试剂盒
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN115028739A (zh) 2017-08-03 2022-09-09 泰加生物工艺学公司 用于治疗黑素瘤的方法和组合物
KR20200066616A (ko) 2017-09-21 2020-06-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
JP2021511293A (ja) * 2018-01-12 2021-05-06 ビラクタ セラピューティクス，インク． 細胞免疫療法で使用されるエピジェネティック修飾因子
AU2019209428A1 (en) 2018-01-22 2020-07-30 Endocyte, Inc. Methods of use for CAR T cells
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US20210246503A1 (en) 2018-06-11 2021-08-12 The Broad Institute, Inc. Lineage tracing using mitochondrial genome mutations and single cell genomics
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US20210177832A1 (en) 2018-08-20 2021-06-17 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
BR112021012278A2 (pt) 2018-12-21 2021-12-14 Biontech Us Inc Método e sistema para a preparação de células hla de classe ii-específica de epitopes e de síntese de cd4 + t
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
JP2023538303A (ja) 2020-08-13 2023-09-07 イェール ユニバーシティー 所望の表現型を有するｃａｒ ｔ細胞の操作および選択のための組成物および方法
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023220644A1 (en) 2022-05-10 2023-11-16 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL224379A (ko) 1957-01-30
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
WO1988001649A1 (en) * 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6463394A (en) * 1987-09-04 1989-03-09 Kyowa Hakko Kogyo Kk Novel chimera polypeptide
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
CA2000878C (en) * 1988-10-18 1999-06-29 Jean-Pierre Kinet Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
FR2644463A1 (ko) * 1989-03-17 1990-09-21 Pasteur Institut
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
WO1991010736A2 (en) * 1990-01-19 1991-07-25 Dana Farber Cancer Institute CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT
KR100246529B1 (ko) * 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6004811A (en) * 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) * 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
NZ241855A (en) * 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
CZ291754B6 (cs) 1993-07-16 2003-05-14 The General Hospital Corporation Proteinový chimerní receptor, terapeutická buňka, DNA kódující chimerní receptor a vektor
US5439819A (en) * 1993-08-27 1995-08-08 The Regents Of The University Of California Chimeric protein tyrosine kinases
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
JP3782521B2 (ja) 1996-08-23 2006-06-07 富士通コンポーネント株式会社 押釦構造およびキーボード

Also Published As

Publication number Publication date
HUT75375A (en) 1997-05-28
EP0750457A4 (en) 1999-03-03
CN1146136A (zh) 1997-03-26
CA2182890C (en) 2008-11-04
FI120264B (fi) 2009-08-31
DE69534589T2 (de) 2006-07-13
US5851828A (en) 1998-12-22
US7094599B2 (en) 2006-08-22
FI963150A0 (fi) 1996-08-12
MX9603384A (es) 1997-12-31
IL112390A (en) 2006-08-20
FI963150A (fi) 1996-10-10
EP0750457A1 (en) 1997-01-02
HU9602182D0 (en) 1996-10-28
JP3832850B2 (ja) 2006-10-11
WO1995021528A1 (en) 1995-08-17
BR9506783A (pt) 1997-10-14
NZ279123A (en) 1998-03-25
ES2249766T3 (es) 2006-04-01
US20030138410A1 (en) 2003-07-24
KR100289253B1 (ko) 2001-11-30
NO963379L (no) 1996-10-11
CZ293969B6 (cs) 2004-09-15
EP0750457B1 (en) 2005-11-09
JPH09512421A (ja) 1997-12-16
UA42760C2 (uk) 2001-11-15
NO963379D0 (no) 1996-08-13
US6284240B1 (en) 2001-09-04
PL315908A1 (en) 1996-12-09
IL112390A0 (en) 1995-03-30
CZ233196A3 (en) 1997-07-16
DK0750457T3 (da) 2006-03-27
CA2182890A1 (en) 1995-08-17
CN1318576C (zh) 2007-05-30
ATE308888T1 (de) 2005-11-15
PL180066B1 (pl) 2000-12-29
DE69534589D1 (de) 2005-12-15
AU1565395A (en) 1995-08-29
NO319378B1 (no) 2005-07-25
HU220100B (hu) 2001-10-28
AU690204B2 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
KR970701004A (ko) 키메라 cd4 수용체-포함 세포에 의한 hiv 감염 세포의 표적화 세포용해
RU97115895A (ru) Переключение клеточного иммунитета, осуществляемое с помощью тирозин-специфических протеинкиназных химер
KR927003847A (ko) 수용체-결합된 신호 변환 경로를 위한 키메라 사슬
RU97115769A (ru) Перенаправление клеточного иммунитета посредством химерных рецептеров
CA2209301A1 (en) Redirection of cellular immunity by protein-tyrosine kinase chimeras
Chaudhary et al. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein
CA2209300A1 (en) Redirection of cellular immunity by receptor chimeras
Curtis et al. Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.
FI964311A0 (fi) Bifunktionaalinen proteiini, valmistus ja käyttö
UA41870C2 (uk) Спосіб направлення клітинної відповіді на інфекційний агент, клітину, інфіковану вказаним агентом, пухлинну, злоякісну клітину або аутоімунну клітину (варіанти), клітина, яка експресує мембранозв'язаний білковий химерний рецептор (варіанти), днк,що кодує химерний рецептор, вектор, спосіб лікування інфекції вірусу імунодефіциту(варіанти)
ES2141076T3 (es) Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
DK0538404T3 (da) Fibroblaste vækstfaktorreceptorer
RU96105032A (ru) Переключение клеточного иммунитета рецепторными химерами
CA2195653A1 (en) Cells bearing cd4 decoy receptors and related molecules and methods
Wang et al. Expression and purification of glutathione S-transferase-tagged HIV-1 gp120: no evidence of an interaction with CD26
Vitetta Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS
Carr et al. Immunoaffinity‐purified opiate receptor specifically binds the δ‐class opiate receptor ligand, cis‐(+)‐3‐methylfentanylisothiocyanate, SUPERFIT
Bäckman‐Petersson et al. Molecular characterization of the novel rat NK receptor 1C7
RU96118239A (ru) Нацеленный цитолиз вич-инфицированных клеток несущими химерный cd4-рецептор клетками
Smythe et al. Production of linear polymers of HIV go120-binding domains
Mack et al. Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1 infection
Traunecker et al. Three generations of recombinant CD4 molecules as anti-HIV reagents
AT503387B1 (de) Pharmazeutische zusammensetzung zur vorbeugung von infektionen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130206

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20140207

Year of fee payment: 14

EXPY Expiration of term